
Inhaltsverzeichnis
Section 1: Introduction. - Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis. - Section 2: Targeting immunometabolism. - Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism. - Chapter 3:The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells. - Chapter 4: HIF-1 as a potential therapeutic target for tuberculosis treatment. - Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis. - Section 3: Enhancing anti-mycobacterial mechanisms. - Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis. - Chapter 7: Metformin: a leading HDT candidate for TB. - Chapter 8: Statins as host-directed therapy for tuberculosis. - Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms. - Section 4: Targeting immune cells. - Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis. - Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma. - Chapter 12: Targeting suppressor T cells. - Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis. - Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis. - Chapter 15: Mucosal-associated invariant and V 9V 2 T cells. - Chapter 16: Airway epithelial cells. -Section 5: Preclinical models for assessing HDTs. - Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies. - Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis. - Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis. - Section 6: Clinical trials of HDTs and special considerations for study endpoints. - Chapter 20:Clinical trials of TB-HDT candidates. - Chapter 21:Outcomes for clinical trials of host-directed therapies for tuberculosis. - Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis.
Es wurden noch keine Bewertungen abgegeben. Schreiben Sie die erste Bewertung zu "Advances in Host-Directed Therapies Against Tuberculosis" und helfen Sie damit anderen bei der Kaufentscheidung.